MXPA05004845A - N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia. - Google Patents

N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.

Info

Publication number
MXPA05004845A
MXPA05004845A MXPA05004845A MXPA05004845A MXPA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A
Authority
MX
Mexico
Prior art keywords
derivatives
oxides
melphalan
states associated
inducible factor
Prior art date
Application number
MXPA05004845A
Other languages
English (en)
Spanish (es)
Inventor
J Welsh Sarah
Original Assignee
Prolx Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolx Pharmaceuticals Corp filed Critical Prolx Pharmaceuticals Corp
Publication of MXPA05004845A publication Critical patent/MXPA05004845A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05004845A 2002-11-06 2003-11-03 N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia. MXPA05004845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/288,888 US20040087556A1 (en) 2002-11-06 2002-11-06 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
PCT/US2003/035226 WO2004043359A2 (en) 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor

Publications (1)

Publication Number Publication Date
MXPA05004845A true MXPA05004845A (es) 2005-10-05

Family

ID=32175991

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004845A MXPA05004845A (es) 2002-11-06 2003-11-03 N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.

Country Status (7)

Country Link
US (2) US20040087556A1 (https=)
EP (1) EP1567476A4 (https=)
JP (1) JP2006508124A (https=)
AU (1) AU2003291282B2 (https=)
CA (1) CA2504496C (https=)
MX (1) MXPA05004845A (https=)
WO (1) WO2004043359A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007828A2 (en) * 2003-07-14 2005-01-27 Prolx Pharmaceuticals, Inc. Regulation of hif protein levels via deubiquitination pathways
WO2009102960A1 (en) * 2008-02-15 2009-08-20 Board Of Regents Of The University Of Texas System Compositions and methods for treating lung cancer
WO2012058325A1 (en) * 2010-10-29 2012-05-03 Oncothyreon Inc. Compounds and methods useful for treatment of diseases mediated by hif-1
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
ES2896882T3 (es) 2014-02-03 2022-02-28 Quadriga Biosciences Inc Beta-aminoácidos beta sustituidos y análogos como agentes quimioterapéuticos
WO2015117146A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
US10349839B2 (en) * 2015-02-27 2019-07-16 Biotronik Se & Co. Implantable pressure sensor device
CN108026026B (zh) 2015-08-03 2021-02-09 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸和类似物及其应用
EP4512819A3 (en) 2015-08-12 2025-08-06 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2020146758A1 (en) 2019-01-10 2020-07-16 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602278A (en) * 1994-10-20 1997-02-11 Kirkpatrick; Lynn N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells

Also Published As

Publication number Publication date
EP1567476A2 (en) 2005-08-31
EP1567476A4 (en) 2008-09-24
WO2004043359A3 (en) 2004-09-10
JP2006508124A (ja) 2006-03-09
WO2004043359B1 (en) 2004-10-28
CA2504496C (en) 2010-05-04
AU2003291282A1 (en) 2004-06-03
WO2004043359A2 (en) 2004-05-27
CA2504496A1 (en) 2004-05-27
AU2003291282B2 (en) 2010-11-11
US7399785B2 (en) 2008-07-15
US20050026872A1 (en) 2005-02-03
US20040087556A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
NO20021358L (no) Alkylendiamin-substituerte heterocykler
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE165825T1 (de) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
MXPA05004845A (es) N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.
MX2022006281A (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
MX2022006370A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso.
ATE286050T1 (de) Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
ATE445617T1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
BRPI0415355A (pt) triarilimidazóis
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung
YU53998A (en) Process for making phenyl heterocycles useful as cox-2 inhibitors
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60013515D1 (de) 4-Arylpiperidinderivate zur Behandlung von Pruritus

Legal Events

Date Code Title Description
FG Grant or registration